Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer. https://t.co/CBqBQtyAZi. #AACRtii21 https://t.co/X2HRObcPGs
6,980 followers
369 followers
Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer https://t.co/mWw4VYn5ln
7,428 followers
Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer https://t.co/PZPG7KIUhp
925 followers
RT @NatRevClinOncol: Levels of MHC-II on tumour cells are predictive of a pCR to durvalumab or pembrolizumab + NAC (ROC AUC, 0.71 (P = 0.01…